Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Investor Relations Contact

For all your investor relations questions, please contact us at IR@sequanamedical.com or use contact details below.

Lies Vanneste

Director IR
Direct: +32 9 298 2864
Mobile: +32 498 053579

Sequana Medical NV
Kortrijksesteenweg 1112
9051 Sint-Denijs Westrem
Belgium

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES